MedPath

comparitive study of caudal clonidine versus dexmedetomidine for post operative analgesia in paediatric patients

Phase 4
Not yet recruiting
Conditions
elective below umblical surgeries
Registration Number
CTRI/2019/12/022479
Lead Sponsor
mgm medical college
Brief Summary

paediatric patients caudal epidural block is one of the safe and effective technique that can provide analgesia for intra operatively and post operatively ,the use of caudal epidural catheters are not popular are  because of the risk of infection. prolongation of the duration of anaesthesia is acheived by addition of various additives such as opiods,alpha 2 agonists, ropivacaine is extensively used because of its less cardiovascular and neurological toxicity. clonidine is an alpha 2 agonist which prolongs the duration and dexmedetomidine has 8 fold higher affinity for alpha 2 adrenergic receptors and much alpha 1 effect. so we conducted the study to compare the post operative duration of analgesis between these drugs

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
84
Inclusion Criteria

1.asa grade 1 and 2 2.children between 2 to 6 age group 3.elective below umblical surgeries.

Exclusion Criteria

1.children with local infection at the caudal region 2.coagulopathy 3.pre existing neurological or obvious spinal diseases 4.history of developmental delay and congenital anomaly 5.known allergy to study drug 6.refusal of parents.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
duration of post operative analgesia0,1,2,4,6,8,10,12,16,20,24 hours
Secondary Outcome Measures
NameTimeMethod
incidence of complications1,2,3,4,8,16,24 hours

Trial Locations

Locations (1)

mgm medical college aurangabad

🇮🇳

Aurangabad, MAHARASHTRA, India

mgm medical college aurangabad
🇮🇳Aurangabad, MAHARASHTRA, India
Rafson
Principal investigator
9500144229
rafson55@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.